Inventory Turnover measures how fast the company turns over its inventory within a year.
Santhera Pharmaceuticals Holding AG's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.17.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Santhera Pharmaceuticals Holding AG's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.48.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Santhera Pharmaceuticals Holding AG's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Santhera Pharmaceuticals Holding AG's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Santhera Pharmaceuticals Holding AG Days Inventory Related Terms
Santhera Pharmaceuticals Holding AG Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG Days Inventory Chart
XSWX:SANN vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Days Inventory distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a Days Inventory of 155.39 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. This is 13% below median its historical median of 177.81. Over the past decade, Santhera Pharmaceuticals Holding AG's Days Inventory has ranged from 27.23 to 792.57. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #240 out of 638 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Santhera Pharmaceuticals Holding AG's Days Inventory too high?
Santhera Pharmaceuticals Holding AG's current Days Inventory of 155.39 is 13% below median its 10-year median of 177.81. Over the past 10 years, this metric has ranged from a low of 27.23 to a high of 792.57. The Biotechnology industry median Days Inventory is 183.88. Santhera Pharmaceuticals Holding AG's value of 155.39 is 15.5% below this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #240 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #240 out of 638 companies for Days Inventory. This puts Santhera Pharmaceuticals Holding AG in the upper half of its industry. The industry median Days Inventory is 183.88. Santhera Pharmaceuticals Holding AG's value of 155.39 is 15.5% below this benchmark. Historically, Santhera Pharmaceuticals Holding AG's own Days Inventory has ranged from 27.23 to 792.57 over the past decade. While the company's 10-year median is 177.81 vs. the industry median of 183.88, Santhera Pharmaceuticals Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current Days Inventory of 155.39 is 15.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Days Inventory is 155.39, which is 13% below median its own 10-year median of 177.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.24, compared to a current price of CHF15.20 — trading 34.6% below its estimated fair value. The current Days Inventory is 155.39, which is 13% below median its 10-year median of 177.81 and 15.5% below the Biotechnology industry median of 183.88. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current Days Inventory is 155.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF15.20 is trading 34.6% below its estimated GF Value™ of CHF23.24.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
Days Inventory: 155.39 (13% below median its 10-year median of 177.81)
GF Value™: CHF23.24 vs. price of CHF15.20 (34.6% below fair value)
Industry Position: 15.5% below the Biotechnology median (#240 of 638)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for XSWX:SANN
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 
